Impact of Treatment with GLP1 Receptor Agonists, Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting List for Bariatric Surgery

Background: Weight loss before undergoing metabolic and bariatric surgery (MBS) has been suggested to reduce perioperative complications, although with controversial results. The objective of this study is to evaluate the impact of treatment with GLP1-R agonists (liraglutide 3.0 mg and semaglutide 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubio-Herrera, Miguel A., Mera-Carreiro, Sara, Sánchez-Pernaute, Andrés, Ramos-Levi, Ana M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604375/
https://www.ncbi.nlm.nih.gov/pubmed/37893158
http://dx.doi.org/10.3390/biomedicines11102785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604375/
https://www.ncbi.nlm.nih.gov/pubmed/37893158
http://dx.doi.org/10.3390/biomedicines11102785

Ejemplares similares